Inhibition of growth in oval squamous carcinoma cells by cyclopentenone prostaglandins: Comparison with chemotherapeutic agents

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 56, Issue 6, 1997, Pages 461-465

  Elattar, T M A ^a   Virji, A S ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA12 PROSTAGLANDIN J2; FLUOROURACIL; METHOTREXATE; PROSTAGLANDIN A1; PROSTAGLANDIN A2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN J2; 16,16 DIMETHYLPROSTAGLANDIN A1; 16,16-DIMETHYLPROSTAGLANDIN A1; 9-DEOXY-DELTA-9-PROSTAGLANDIN D2; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROSTAGLANDIN A; PROSTAGLANDIN D2;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; DNA SYNTHESIS; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; CELL CULTURE; CELL DIVISION; COMPARATIVE STUDY; MOUTH TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DINOPROSTONE; FLUOROURACIL; HUMANS; METHOTREXATE; MOUTH NEOPLASMS; PROSTAGLANDIN D2; PROSTAGLANDINS A; PROSTAGLANDINS A, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC; TUMOR CELLS, CULTURED; VITAMIN E;

EID: 0030610724     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(97)90600-1     Document Type: Article

References (33)

1. Honn K. V., Bockman R. S., Marnett L. J. Prostagladins and Cancer. A review of tumor initiation through tumor metastasis. Prostaglandins 1981; 21: 833-864.
2. 2 - anti-tumor and anti-viral activities and the mechanisms involved. Eicosanoids 1990; 3: 189-199.
3. Hughes-Fulford M., Wu J., Fukushima M. Inhibition of DNA synthesis and cell cycle by prostaglandins independent of cyclic AMP. In: Advances in Prostaglandin Thromboxane and Leukotriene research, Vol. 15, New York: Raven Press, 1985: 401-404.
4. Negishi M., Sugimoto Y., Ichikawa A. Prostanoid receptors and their biological actions. Prog Lipid Res 1993; 32: 417-434.
5. Ohno K., Fukushima M., Fujiwara M., Narumiya S. Induction of 68 000-dalton heat shock proteins by cyclopentenone prostaglandins. J Biol Chem 1988; 263: 19764-19770.
6. 2 formed in human plasma. Proc Natl Acad Sci USA 1984; 81: 1317-1321.
7. 2 and cellular uptake of the dehydration product: Correlation with prostaglandin E-induced growth inhibition. Biochem Biophys Res Commun 1986; 139: 808-815.
8. Honn K. V., Marnett L.J. Requirement of a Reachive α, B-unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by 'A' series Prostaglandins. Biochem Biophys Res Commun 1985; 129: 34-40.
9. 2 in vitro and in vivo. Cancer Res 1986; 46: 3538-3542.
10. Sasaki H., Fukushima M. Prostaglandins in the treatment of cancer. Anti-cancer drugs 1994; 5: 131-138.
11. 2, a new anti-viral prostaglandin: inhibition of Sendai virus replication and alteration of virus protein synthesis. J Gen Virol 1987; 68: 1153-1158.
12. 2 against HTLV-I-Infected MT-2 Cells. Int J Cancer 1992; 51: 481-488.
13. 2 in vitro and in vivo. Cancer Res 1986; 46: 3538-3542.
14. Kikuchi Y., Kita T., Miyanchi M. et al. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells. J Cancer Res Clin Oncol 1992; 118: 453-457.
15. 2 and vitamin E succinate. J Oral Path Med 1993; 22: 425-427.
16. ElAttar T. M. A., Lin H. S. Vitamin E succinate potentiates the inhibitary effect of prostaglandins on oral squamous carcinoma cell proliferation. Prostaglandin Leukot Essent Fatty Acids 1995; 52: 69-73.
17. Rheinwald J. G., Beckett M. A. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 1981; 41: 1657-1663.
18. Modtahedi H., Styles J., Dean C. The growth response of human tumor cell lines expressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding. Int J Oncology 1993; 3: 237-243.
19. 2: Comparison with Chemotherapeutic Agents.
20. 1; Cancer Res 1983; 43: 1642-1645.
21. Bergman M. D., Funk C., Fukushima M. Inhibition of human melanoma growth by prostaglandin A, D and J analogues. Cancer Research 1986; 46: 2740-2744.
22. 2 in human and murine melanoma cells in culture. Cancer Res 1986; 46: 1688-1693.
23. Narumiya S., Ohno K., Fujiwara M., Fukushima M. Site and mechanism of growth inhibition by prostaglandins II. Temperature - dependent transfer of a cyclopentenone prostaglandins to nuclei. J Pharmacol Exp Ther 1986; 239: 506-511.
24. 2 in nuclei. J Pharmacol Exp Ther 1987; 242: 306-311.
25. 3 Cells. J Pharmacol Exp Ther 1988; 245: 294-298.
26. 2-induced protein syntheses in porcine aortic endothelial cells. Biochem Pharmacol 1992; 44: 1597-1602.
27. 2 on c-myc expression and cell cycle progression in human leukemia cell line HL-60. Cancer Res 1988; 48: 2813-2818.
28. 2 induce apoptosis in L1210 cells. FEBS Lett 1993; 321: 209-214.
29. Prasad K. N., Edwards-Prasad J. Vitamin E and cancer prevention: Recent Advances and Future Potentials. J Am Coll Nutr 1992, 11: 487-500.
30. Kline K., Sanders B. Anti-tumor proliferation properties of vitamin E. In: Jacob M., ed. Vitamins and Minerals in the Prevention and Treatment of Cancer. Boca Raton: CRC Press, 1991: 189.
31. Turley J. M., Sanders B. G., Kline K. RRR-α-Tocopheryl succinate modulation of human promyelocytic Leukemia (HL-60) cell proliferation and differentiation. Nutr Cancer 1992; 18: 201-213.
32. Qian M., Sanders B. G., Kline K. RRR-α-Tocopheryl succinate induces apoptosis in avian retrovirus-transformed lymphoid cells. Nutr Cancer 1996, 25: 9-26.
33. Schwartz J., Shklar G., Trickier D., p53 in the anti-cancer mechanism of vitamin E. Oral Oncol, Eur J Cancer 1993; 29B: 313-318.